Cargando…

Comparison of the 9-Month Intrastent Condition and 30-Month Clinical Outcomes After Resolute Zotarolimus-Eluting Stent Implantation Between Standard-Duration and 1-Month Dual Antiplatelet Therapy Followed by Prasugrel Monotherapy

Background: In this study we investigated the efficacy and safety of very short duration (1-month) dual antiplatelet therapy (DAPT) followed by prasugrel monotherapy. In particular, we compared intrastent conditions using optical coherence tomography (OCT) after second-generation drug-eluting stent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamana, Tomoyo, Sawada, Takahiro, Fujimoto, Wataru, Osue, Tsuyoshi, Tsukiyama, Yoshiro, Uzu, Kenzo, Takaya, Tomofumi, Yasaka, Yoshinori, Kawai, Hiroya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939786/ https://www.ncbi.nlm.nih.gov/pubmed/33693290 http://dx.doi.org/10.1253/circrep.CR-20-0126

Ejemplares similares

Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease
por: Wada, Tadashi, et al.
Publicado: (2013)

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients
por: Kandzari, David E., et al.
Publicado: (2020)

Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis
por: Loomba, Rohit S., et al.
Publicado: (2011)

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents
por: Kim, J-S, et al.
Publicado: (2009)

Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea
por: Lee, Joo Myung, et al.
Publicado: (2013)

Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry
por: Jain, Ajay K, et al.
Publicado: (2010)

Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study
por: Roleder, Tomasz, et al.
Publicado: (2019)

Zotarolimus-eluting stent-induced hypersensitivity pneumonitis
por: Shin, Hong-Won, et al.
Publicado: (2013)

Additional ablation effect of low‐speed rotational atherectomy following high‐speed rotational atherectomy on early calcified in‐stent restenosis: A case report
por: Hamana, Tomoyo, et al.
Publicado: (2021)

Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression
por: Villablanca, Pedro A., et al.
Publicado: (2016)

Intrastent haematoma after treatment with a drug-eluting balloon for in-stent restenosis: a case report
por: Hong, Xu-Lin, et al.
Publicado: (2021)

A case report of a perigraft inflammatory reaction to a Viabahn stent-graft: diagnosis with MRI and treatment with steroids
por: Yamamoto, Tetsuya, et al.
Publicado: (2020)

Very Late Stent Thrombosis 42 Months after Implantation of Sirolimus-Eluting Stent and Discontinuation of Antiplatelet Therapy
por: Sibbing, Dirk, et al.
Publicado: (2009)

Advances in drug eluting stents – focus on the Endeavor(®) zotarolimus stent
por: Bridges, Jonathan, et al.
Publicado: (2008)

Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease
por: Sawada, Takahiro, et al.
Publicado: (2020)

Aspirin Monotherapy beyond 12 Months of Dual Antiplatelet Therapy in Patients with Acute Myocardial Infarction: Oldies But Goodies?
por: Suh, Jung-Won
Publicado: (2019)

One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients
por: Pivato, Carlo A., et al.
Publicado: (2022)

Simultaneous Multi-Vessel Subacute Stent Thromboses in Zotarolimus-Eluting Stents
por: Kim, Yong-Hyun, et al.
Publicado: (2010)

Zotarolimus-eluting stent fracture at initial implantation diagnosed with StentBoost
por: Arat Ozkan, Alev, et al.
Publicado: (2016)

Stentless percutaneous coronary intervention with directional coronary atherectomy and drug-coated balloon angioplasty in worsening angina patients with metal allergies
por: Yamamoto, Hiroyuki, et al.
Publicado: (2022)

Rare complications of Guideplus guide-extension catheter during complex percutaneous coronary intervention
por: Shoda, Mitsuhiko, et al.
Publicado: (2022)

Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial
por: Gutiérrez-Chico, Juan Luis, et al.
Publicado: (2011)

Correction to: One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients
Publicado: (2022)

Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent
por: Yoon, Yong-Hoon, et al.
Publicado: (2022)

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial
por: Kedhi, Elvin, et al.
Publicado: (2018)

The Resolute™ Integrity Zotarolimus-Eluting Stent in Coronary Artery Disease: A Review
por: Banerjee, Subhash
Publicado: (2013)

Two Cases of Immediate Stent Fracture after Zotarolimus-Eluting Stent Implantation
por: Lee, Pil Hyung, et al.
Publicado: (2015)

Longitudinal deformation of a third generation zotarolimus eluting stent: “The concertina returns!”
por: Panoulas, Vasileios F, et al.
Publicado: (2017)

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
por: Obayashi, Yuki, et al.
Publicado: (2022)

Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry
por: Maeng, Michael, et al.
Publicado: (2012)

Assessing intrastate shipments from interstate data and expert opinion
por: Brommesson, Peter, et al.
Publicado: (2021)

Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
por: Hillegass, William B, et al.
Publicado: (2011)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada
por: Lordkipanidzé, Marie, et al.
Publicado: (2020)

Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months
por: Lee, Dongwhane, et al.
Publicado: (2019)

Four months of rifampicin monotherapy for latent tuberculosis infection in children
por: Oh, Chi Eun, et al.
Publicado: (2021)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial
por: Lee, Yong-Joon, et al.
Publicado: (2021)

Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model
por: Lim, Kyung Seob, et al.
Publicado: (2013)

One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent
por: Tam, Chor Cheung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_usmjk1eijbfo740q3b0rfp7uif